Recipharm and Moderna Finalize Agreement to Support Formulation and Fill-Finish a part of the Moderna COVID-19 Vaccine Supply Outside of the U.S.

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France.

Subject to regulatory approval of the immunization in important nations outside of the U.S., it is anticipated that supply will commence in early 2021.

“We are making important progress in the development of the Moderna COVID-19 Vaccine and we are pleased to be entering into this collaboration with Recipharm,” said Nicolas Chornet, Senior Vice President, International Manufacturing of Moderna. “We look forward to their support in the delivery of our vaccine to market.”